Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12621294 | 0.86 | KMT2A (0.35) | ATMKDM4EPDE3BPDE3A | |
| SCHEMBL12149774 | 0.76 | TYMP (0.38) | — | |
| SCHEMBL25004045 | 0.69 | PARP1 (0.47) | KDM4E | |
| SCHEMBL32675967 | 0.68 | — | — | |
| SCHEMBL6850855 | 0.65 | DAO (0.38) | — | |
| SCHEMBL12149773 | 0.64 | CYP1A2 (0.32) | KDM4E | |
| SCHEMBL12621292 | 0.64 | ALDH1A1 (0.50) | KDM4E | |
| SCHEMBL13093764 | 0.63 | GRIN2D (0.45) | ATMKDM4EPDE3BPDE3A | |
| SCHEMBL9881405 | 0.62 | ALDH1A1 (0.39) | KDM4E | |
| SCHEMBL19051340 | 0.60 | RXFP1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | ATM 355/4885KDM4E 3087/4885PDE3B 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.